Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Use of Overseas Data Recommended to Develop Pediatric Drugs
January 15, 2001
- Use New Technology to Meet Existing Needs in Healthcare: Mr Tanimura
January 15, 2001
- BUSINESS NEWS IN BRIEF -2-
January 15, 2001
- CPAC to Become Pharmaceutical Affairs and Food Sanitation Council
January 15, 2001
- BASF Sells Pharma Business to Abbott
January 1, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
January 1, 2001
- Takepron Approved for Maintenance Therapy of Recurrent Reflux Esophagitis
January 1, 2001
- Business of Major Drugstore Chain Operators Continues to Expand
January 1, 2001
- JPMA to Work More Closely with Patients' Organizations
January 1, 2001
- Matsumotokiyoshi: Consolidated Half-year Sales Reach ¥115 Bil.
January 1, 2001
- Health Minister Stresses Need for Government to Support Genomic Research: 1st JPMA Forum
January 1, 2001
- Ten More Items to Be Allowed to Be Advertised by Medical Facilities
January 1, 2001
- BUSINESS NEWS IN BRIEF
January 1, 2001
- Tsuruha Acquires Drug Tomato in Iwate
January 1, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 1, 2001
- Kaletra Included in NHI List
January 1, 2001
- Fukuda Denshi to Charge Customers for Maintenance Services
January 1, 2001
- Welfide Licenses Glaucoma Treatment to Senju
January 1, 2001
- NHI Price Listing of Relenza, Tamiflu No Sooner Than Mid February
January 1, 2001
- OTC NEWS IN BRIEF
January 1, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…